EC approves expanded use of CAR T-cell therapy Breyanzi for r/r mantle cell lymphoma

European Commission authorizes expanded label for Venclyxto to include additional combinations in previously untreated CLL

The European Commission authorized an expanded label for Venclyxto (venetoclax) to include use in combination with acalabrutinib (with or without obinutuzumab) and use in combination with ibrutinib for the treatment of adult patients with previously untreated chronic lymphocytic leukemia.

June 05, 2026

Vol.52 No.22

Clinical Roundup

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a cytokine-armored CAR T-cell therapy that helps the immune system better attack aggressive brain tumors in mice while reducing dangerous side effects that have long limited immune-based treatments for glioblastoma, one of the deadliest and most treatment-resistant brain cancers.

May 29, 2026

Vol.52 No.21

Clinical Roundup

Winship first in U.S. to administer in vivo CAR-T therapy in myeloma trial

Physicians and researchers at Winship Cancer Institute of Emory University announced they have administered the first investigational in vivo CAR-T cell therapy in the United States for relapsed and refractory multiple myeloma.

May 22, 2026

Vol.52 No.20

Guest Editorial

Directing the narrative of your survival: How The Remission Film Festival centers survivorship stories

Cancer survivorship in the United States now tops 18 million people. That is a lot of people walking around with a shared experience, and yet somehow we barely talk about what surviving cancer actually does to you.

April 24, 2026

Vol.52 No.16

By Edward Miskie

Clinical Roundup

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

In the phase II CAR-PRISM (PRecision Intervention Smoldering Myeloma) clinical trial, the first to investigate CAR T-cell therapy in patients with high-risk smoldering multiple myeloma, all 20 patients were negative for minimal residual disease within two months of treatment and remained MRD-negative after a median of 15.3 months of follow-up.

April 24, 2026

Vol.52 No.16

Drugs & Targets

EU approves Ojemda as first targeted therapy in r/r pediatric low-grade glioma regardless of BRAF alteration

The European Commission has granted conditional marketing authorization for Ojemda (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with pediatric low-grade-glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies.

April 24, 2026

Vol.52 No.16

EC approves expanded use of CAR T-cell therapy Breyanzi for r/r mantle cell lymphoma

YOU MAY BE INTERESTED IN

European Commission authorizes expanded label for Venclyxto to include additional combinations in previously untreated CLL

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

Winship first in U.S. to administer in vivo CAR-T therapy in myeloma trial

Directing the narrative of your survival: How The Remission Film Festival centers survivorship stories

CAR T-cell therapy for high-risk smoldering MM shows deep and lasting responses in phase II study

EU approves Ojemda as first targeted therapy in r/r pediatric low-grade glioma regardless of BRAF alteration

Renew today!

Subscriber content

Never miss an issue!

Login